DORA and LP in Alzheimer's Disease Biomarkers

Recruiting Phase 2 Interventional Study
Alzheimer Disease
Ready to participate?

Review the details below, then apply to join this clinical trial.

Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

The purpose of this study is to see if the sleep aid, lemborexant, can decrease the amount of amyloid-beta and tau in the blood. Amyloid-beta and tau are proteins involved in the disease process leading to Alzheimer's disease.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Male or female. * Any race or ethnicity. * Participants must be age ≥ 65 years and able to sign informed consent. * Global Clinical Dementia Rating (CDR) 0. * Willing and able to undergo study procedures. Exclusion Criteria: * History or reported symptoms suggestive of restl…
Contacts

Chloe Meehan, MA

314-273-0878

cmeehan@wustl.edu

CONTACT

Crirstina Toedebusch

314-747-0646

toedebuschc@wustl.edu

CONTACT